ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2015
Intestinal secretory mechanisms in irritable bowel syndrome-diarrhea.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06904872 (A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Natural products for the management of diarrhea: a systematic review of clinical efficacy, safety, and certainty of evidence.Frontiers in pharmacology · 2026Pooled it
- Effects of fecal microbiota transplantation in subjects with irritable bowel syndrome are mirrored by changes in gut microbiome.Gut microbes · 2020Trial
- Altered Sigmoid Mucosal Innervation and Mast Cell Proximity to Sensory Nerve Fibers Are Associated With Symptom Severity in Patients With Irritable Bowel Syndrome.Neurogastroenterology and motility · 2025Article
- Article
- The role of the gut microbiome in disorders of gut-brain interaction.The FEBS journal · 2025Review
- Roles and regulation of Aquaporin-3 in maintaining the gut health: an updated review.Frontiers in physiology · 2023Review
- Therapeutic effects of curcumin on constipation-predominant irritable bowel syndrome is associated with modulating gut microbiota and neurotransmitters.Frontiers in microbiology · 2023Article
- SAHA Alleviates Diarrhea-Predominant Irritable Bowel Syndrome Through Regulation of the p-STAT3/SERT/5-HT Signaling Pathway.Journal of inflammation research · 2022Article
- Flupirtine enhances NHE-3-mediated NaAmerican journal of physiology. Gastrointestinal and liver physiology · 2021Article
- Activation ofAmerican journal of physiology. Cell physiology · 2021Article
- The trace aminergic system: a gender-sensitive therapeutic target for IBS?Journal of biomedical science · 2020Review
- Aquaporin Expression in Colonic Mucosal Biopsies From Irritable Bowel Syndrome With Diarrhea.Clinical and translational gastroenterology · 2019Article
- Tong-Xie-Yao-Fang Regulates 5-HT Level in Diarrhea Predominant Irritable Bowel Syndrome Through Gut Microbiota Modulation.Frontiers in pharmacology · 2018Article
- Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea.Gastroenterology · 2017Review
- Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside.Journal of neurogastroenterology and motility · 2016Review
- Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.Alimentary pharmacology & therapeutics · 2015Review
- Colonic mucosal gene expression and genotype in irritable bowel syndrome patients with normal or elevated fecal bile acid excretion.American journal of physiology. Gastrointestinal and liver physiology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Although diarrhea is the predominant bowel dysfunction in as many as one-third of patients with irritable bowel syndrome (IBS), it is unclear whether there is a specific disorder of intestinal fluid or electrolyte secretion in IBS. Diarrhea is generally considered a result of accelerated colonic transit in patients with IBS. Although a primary secretory diathesis has not been well-documented in patients with IBS with diarrhea (IBS-D), several mechanisms that could potentially contribute to intestinal secretion have been reported. Some of these mechanisms also influence motor and secretory dysfunctions that contribute to the pathophysiology of IBS-D. We review the evidence supporting secretion in IBS-D caused by peptides and amines produced by enteroendocrine cells or submucosal neurons, enterocyte secretory processes, and intraluminal factors (bile acids and short-chain fatty acids). Understanding these mechanisms and developing clinical methods for their identification could improve management of patients with IBS-D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.